Abstract
PRAX-114 is an extrasynaptic-preferring GABAA receptor positive allosteric modulator in development for treatment of major depressive disorder (MDD). Extrasynaptic preference was hypothesized to explain preclinical findings demonstrating >20-fold separation between antidepressant- and sedative-like doses in rodents, and the lack of dose-limiting sedation in a Phase 1 trial assessing PRAX-114 safety and tolerability in healthy participants. Here we report results from an open-label Phase 2 trial assessing safety, tolerability and preliminary efficacy in MDD.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
